DeCure for Congenital dyserythropoietic anemia type 2
DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for congenital dyserythropoietic anemia type 2 — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleCongenital dyserythropoietic anemia type 2 maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for congenital dyserythropoietic anemia type 2 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
A 2017 case report describes the fifth known patient with congenital dyserythropoietic anaemia type IV, identified after genetic study of a previously unclassified CDA. The authors note that the wide variety of phenotypes makes differential diagnosis difficult and that identification of genetic variants is crucial for clinical management. No treatment or drug is mentioned in this report.
A 2009 report describes a patient whose anaemia showed erythroblastic multinuclearity, ineffective erythropoiesis, a negative acidified serum test, a negative sugar water test, a significantly positive cold antibody lysis test (anti-I), and no evidence of anti-i. The electron microscopic features were compatible with both types I and II CDA. No drug or treatment is discussed.
A 1985 family study describes a mild anaemia with marked dyserythropoiesis, prominent ringed sideroblasts, autosomal recessive inheritance, marked microcytosis, poikilocytosis, mild haemolysis, slightly increased haemoglobin A2, bone marrow erythroid hyperplasia, and non-specific structural abnormalities of erythroid precursors on electron microscopy. The authors propose the designation 'variant congenital dyserythropoietic anaemia with ringed sideroblasts' as a previously unreported type. No drug or treatment is mentioned.
No abstract in this set reports any drug being tested or repurposed for congenital dyserythropoietic anaemia type II or any other CDA subtype. What is missing is any clinical trial, any drug intervention data, any patient stratification beyond single-case or family reports, and any funding for systematic therapeutic studies in these rare anaemias.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Clinical Case Reports · 2017 · 30 citations · open access
A case of congenital dyserythropoietic anemia type IV
AbstractCongenital dyserythropoietic anemias (CDAs) are displayed by ineffective erythropoiesis. The wide variety of phenotypes observed in CDA patients makes differential diagnosis difficult; identification of the genetic variants is crucial in clinical management. We report the fifth case of a patient with unclassified CDAs, after genetic study, with CDA type IV.
Congenital Dyserythropoietic Anemia with Ultrastructure Findings Compatible with both Types I and II
AbstractA patient with congenital dyserythropoietic anemia with serological findings and electron microscopic features compatible with those of types I and II is described. The anemia was characterized by erythroblastic multinuclearity, ineffective erythropoiesis, negative acidified serum test and negative sugar water test. The cold antibody lysis test (anti-I) was significantly positive and there was no evidence of anti-i.
Variant congenital dyserythropoietic anaemia with ringed sideroblasts
AbstractA family is described with mild anaemia characterized by marked dyserythropoiesis and by prominent ringed sideroblasts. Inheritance is autosomal recessive. Other features include marked microcytosis, poikilocytosis, mild haemolysis, slightly increased haemoglobin A2, bone marrow erythroid hyperplasia and non-specific structural abnormalities of erythroid precursors on electron microscopy. This appears to be a previously unreported type of hereditary anaemia with both dyserythropoiesis and ringed sideroblasts. We propose the designation 'variant congenital dyserythropoietic anaemia with ringed sideroblasts'.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
